143 related articles for article (PubMed ID: 19689297)
21. Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
Huang Y; Goel S; Duda DG; Fukumura D; Jain RK
Cancer Res; 2013 May; 73(10):2943-8. PubMed ID: 23440426
[TBL] [Abstract][Full Text] [Related]
22. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
Gabrilovich DI; Ishida T; Nadaf S; Ohm JE; Carbone DP
Clin Cancer Res; 1999 Oct; 5(10):2963-70. PubMed ID: 10537366
[TBL] [Abstract][Full Text] [Related]
23. Activated human CD4+ T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-beta: implications for dendritic cell immunization against cancer.
Lin CM; Wang FH; Lee PK
Clin Immunol; 2002 Jan; 102(1):96-105. PubMed ID: 11781072
[TBL] [Abstract][Full Text] [Related]
24. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells.
Dallas NA; Fan F; Gray MJ; Van Buren G; Lim SJ; Xia L; Ellis LM
Cancer Metastasis Rev; 2007 Dec; 26(3-4):433-41. PubMed ID: 17786539
[TBL] [Abstract][Full Text] [Related]
25. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
Rolinski J; Hus I
J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory Activity of VEGF in Cancer.
Lapeyre-Prost A; Terme M; Pernot S; Pointet AL; Voron T; Tartour E; Taieb J
Int Rev Cell Mol Biol; 2017; 330():295-342. PubMed ID: 28215534
[TBL] [Abstract][Full Text] [Related]
27. [Vascular endothelial growth factor. From basic research to clinical application].
Smirne C; Camandona M; Rosso E; Bellone G; Emanuelli G
Minerva Med; 1999; 90(1-2):15-23. PubMed ID: 10388459
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.
Oyama T; Ran S; Ishida T; Nadaf S; Kerr L; Carbone DP; Gabrilovich DI
J Immunol; 1998 Feb; 160(3):1224-32. PubMed ID: 9570538
[TBL] [Abstract][Full Text] [Related]
29. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.
Wada J; Suzuki H; Fuchino R; Yamasaki A; Nagai S; Yanai K; Koga K; Nakamura M; Tanaka M; Morisaki T; Katano M
Anticancer Res; 2009 Mar; 29(3):881-8. PubMed ID: 19414323
[TBL] [Abstract][Full Text] [Related]
30. Vascular endothelial growth factor and its inhibitors.
Verheul HM; Pinedo HM
Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
[TBL] [Abstract][Full Text] [Related]
31. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy.
Appelmann I; Liersch R; Kessler T; Mesters RM; Berdel WE
Recent Results Cancer Res; 2010; 180():51-81. PubMed ID: 20033378
[TBL] [Abstract][Full Text] [Related]
32. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.
Kandalaft LE; Motz GT; Busch J; Coukos G
Curr Top Microbiol Immunol; 2011; 344():129-48. PubMed ID: 20680802
[TBL] [Abstract][Full Text] [Related]
33. Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies.
Darvishi B; Majidzadeh-A K; Ghadirian R; Mosayebzadeh M; Farahmand L
Life Sci; 2019 Jan; 217():34-40. PubMed ID: 30472294
[TBL] [Abstract][Full Text] [Related]
34. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.
Almand B; Clark JI; Nikitina E; van Beynen J; English NR; Knight SC; Carbone DP; Gabrilovich DI
J Immunol; 2001 Jan; 166(1):678-89. PubMed ID: 11123353
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor affects dendritic cell activity in hypertensive disorders of pregnancy.
Wang J; Tao YM; Cheng XY; Zhu TF; Chen ZF; Yao H; Su LX
Mol Med Rep; 2015 Sep; 12(3):3781-3786. PubMed ID: 25975204
[TBL] [Abstract][Full Text] [Related]
36. [Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma].
Fan XH; Han BH; Dong QG; Sha HF; Bao GL; Liao ML
Zhonghua Jie He He Hu Xi Za Zhi; 2003 Sep; 26(9):539-43. PubMed ID: 14521757
[TBL] [Abstract][Full Text] [Related]
37. Ovarian carcinoma cells effectively inhibit differentiation and maturation of dendritic cells derived from hematopoietic progenitor cells in vitro.
Ye F; Chen HZ; Xie X; Ye DF; Lu WG
Cancer Invest; 2005; 23(5):379-85. PubMed ID: 16193636
[TBL] [Abstract][Full Text] [Related]
38. A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays.
Weinzierl AO; Maurer D; Altenberend F; Schneiderhan-Marra N; Klingel K; Schoor O; Wernet D; Joos T; Rammensee HG; Stevanović S
Cancer Res; 2008 Apr; 68(7):2447-54. PubMed ID: 18381453
[TBL] [Abstract][Full Text] [Related]
39. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
40. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
